Improving Quality of Care

ASH develops evidence-based resources and tools for clinicians to improve care in their hospital or health system.

 

In 2023, Blood Advances published new ASH Clinical Practice Guidelines on Thrombophilia Testing and the Management of VTE in Special Populations in Latin America. New ASH guidelines are under development, including ones on diagnosis of amyloidosis, pediatric venous thromboembolism, aplastic anemia, and acute myeloid leukemia in older adults (revision).

 

ASH launched the new Quality Improvement Training Institute (QITI), a 16-month, hybrid educational training program that trains clinicians to be leaders in quality improvement. QITI will welcome five multidisciplinary hematologic care teams to its inaugural cohort in 2024.

“QITI will be ASH’s first ever hematology-focused QI training program. This program will help providers understand what QI is about at its core and teach them not only how to just meet metrics, but also how to better identify and meet patient needs.”

Michael Keng, MD

QITI Director and Chair, Quality Improvement Training and Education Subcommittee

ASH recognized Gabrielle Nguyen, MD at the University of Texas, Southwestern Medical Center, and Christina Ruiz, MD at Rady Children’s Hospital, University of California, San Diego, as the 2023 Guideline Implementation Champions at the 2023 ASH Annual Meeting. Their projects focused on improving care for people with sickle cell disease.

Consult a Colleague

ASH connected 142 clinicians with their peers to facilitate exchange of information between hematologists on complex clinical cases through the Consult a Colleague program.

VTE Thrombophilia Testing

Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). A multidisciplinary panel agreed on 23 recommendations regarding thrombophilia testing and associated management.

Management of VTE in Special Populations in Latin America

The implementation of guidelines in Latin America requires additional deliberations, such as values, preferences, accessibility, feasibility, and more. ASH and 12 local hematology societies formed a panel to consider the management of VTE with these considerations.

Explore the 2023 Annual Report